New Delhi: Russia is looking for a partnership with India for producing COVID-19 vaccine Sputnik V, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF), said on Thursday.

Russian President Vladimir Putin had announced that his country has developed the world's first vaccine against COVID-19, which works "quite effectively" and forms a "stable immunity" against the disease.

Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the RDIF. The vaccine has not been tested in Phase 3 or larger clinical trials.

Addressing an online press briefing, Dmitriev said several nations are interested in the production of the vaccine from countries in Latin America, Asia and the Middle East.

"The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have," he said.

Dmitriev said Russia is looking forward to international cooperation.

"We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India. We are planning to produce the vaccine in more than five countries and there is a very high demand from Asia, Latin America, Italy and other parts of the world regarding the delivery of the vaccine," he said.

Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology and an academician at the Russian Academy of Sciences, said more than 20,000 people have taken part in the clinical trials of vaccines and drugs, based on human adenoviruses or human adenoviral vectors.

"Vaccines do not contain live human adenoviruses, but human adenovirus vectors, that is, human viruses that cannot multiply in the body and are completely safe," he said.

The Sputnik V vaccine consists of two shots that use different versions of adenoviruses -- virus types, some of which cause the common cold -- that the manufacturers have engineered to carry the gene for the surface protein of SARS-CoV-2 that causes COVID-19.

"The approach of the Gamaleya Institute with the vaccine, using two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has a clear advantage over the one-vector approach used by other developers," Gintsburg said.

 

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



Bengaluru: In a major crackdown on drug trafficking and illegal narcotics trade, Bengaluru City Police have arrested 16 accused persons and seized narcotic substances worth Rs 36.67 crore.

According to Bengaluru City Police Commissioner Seemanth Kumar Singh, those arrested include four foreign nationals, eight persons from other states and four locals. Police said the network had interstate as well as international links.

Police recovered 9 kg 64 grams of MDMA, 5 kg 195 grams of hydro ganja, 19,755 LSD strips, 156 grams of heroin, 618 grams of charas, 332 grams of cocaine, 315 grams of drug-mixed gummies and 11 kg 470 grams of ganja from the accused.

The Commissioner said the action was carried out as part of a major anti-drug operation in the city. The network was busted with the support of the CCB Narcotics Control Squad and police stations of Bagaluru, Adugodi, Chikkajala, HSR Layout, Yeshwanthpur, Jalahalli and Jnanabharathi.

Cases were registered in CCB, East Division and West Division police stations based on specific intelligence received on different dates, following which raids were conducted.

Preliminary investigation revealed that the accused were procuring drugs at lower prices from foreign, interstate and local sources and selling them in Bengaluru at higher rates.

Police said college students and working professionals were among the main targets of the accused.